We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Critical Care

Multicomponent Pulmonary Rehabilitation Significantly Enhances Weaning Outcomes in Elderly Patients on Prolonged Mechanical Ventilation

MedXY Editorial Team•Sep 30, 2026•Critical Care
elderly patientspulmonary rehabilitation

Highlight

  • Multicomponent pulmonary rehabilitation significantly increased successful ventilator weaning rates in patients aged 80 years or older receiving prolonged mechanical ventilation.
  • Physiological parameters including oxygen saturation off ventilation, diaphragm muscle function, cough strength, and overall muscle strength improved substantially with the intervention.
  • Incidence of ventilator-associated pneumonia (VAP) was reduced at 60 and 90 days in patients receiving the rehabilitation program.
  • No increase in deep vein thrombosis (DVT) or mortality was observed, indicating safety of the multicomponent rehabilitation approach in this frail population.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Technical and Clinical Feasibility of a Pulmonary Telerehabilitation Model for People with COPD: A Comprehensive ReviewThis review synthesizes evidence on the feasibility, acceptance, and clinical outcomes of pulmonary telerehabilitation models in COPD, highlighting technical reliability, patient adherence, and clinical benefits from recent trials, includinOct 18, 2026First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant PatientsThe phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid maSep 22, 2026Evaluating High Intensity Interval Training Versus Moderate Intensity Continuous Training in Fibrotic Interstitial Lung Disease: Insights from a Randomized Controlled TrialA randomized trial compared high intensity interval training (HIIT) with standard moderate intensity continuous training (MICT) in fibrotic interstitial lung disease, finding no superiority of HIIT but confirming its safety and feasibility.Sep 20, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell CarcinomaIn elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. PersonalizeSep 14, 2026
Temporal Trends in Oral Anticoagulant Use and Clinical Outcomes Among Older Adults with Atrial Fibrillation: Insights from a Danish Nationwide Study and Contemporary EvidenceRecent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.Jul 16, 2026
Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid LeukemiaOral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particulaJul 9, 2026